DMPI - DelMar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-
Cost of Revenue-
Gross Profit-
Operating Expenses
Research Development-
Selling General and Administrative-
Non Recurring-
Total Operating Expenses8,405.923
Operating Income or Loss-8,405.923
Income from Continuing Operations
Total Other Income/Expenses Net-
Earnings Before Interest and Taxes-8,405.923
Interest Expense-
Income Before Tax-
Income Tax Expense-
Minority Interest-
Net Income From Continuing Ops-
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect Of Accounting Changes-
Other Items-
Net Income
Net Income-8,081.764
Preferred Stock And Other Adjustments-
Net Income Applicable To Common Shares-